Dr. Atillasoy, Chief Regulatory and Safety Officer, has nearly 25 years of experience leading drug, biologic, and infectious disease product development. Prior to joining AlloVir, Dr. Atillasoy was at Merck Research Laboratories serving as Vice President and Therapeutic Area Head of Vaccines and Infectious Disease in Global Regulatory Affairs and Clinical Safety. He had responsibility and oversight for Merck’s extensive portfolio of infectious disease products, many of which have transformed human health. In addition, he oversaw engagement and strategy with regulatory agencies across the world, including those in theUnited States, Europe, Japan, and China.
Dr. Atillasoy joined Merck in 2001 and played an instrumental role in expediting development and approval of novel medicines and vaccines that have changed the world, including vaccines against viruses, such as Ebola (Ervebo®), human papillomaviruses that cause cancers (Gardasil® and Gardasil® 9), rotaviruses (RotaTeq®), those that cause pediatric illnesses (ProQuad®, Vaxelis™). Most recently, he had regulatory oversight for Merck’s lead investigational COVID-19-related vaccine and small molecule programs. Dr. Atillasoy has led regulatory filings and approvals for many antiviral agents, such as those against HIV (Isentress®, Delstrigo™, Pifeltro™), cytomegalovirus (Prevymis™) and hepatitis C (Zepatier®). In addition, Dr. Atillasoy oversaw the first IND filing for Keytruda® for melanoma, and he has supported approval of other oncology products that include Zolinza®, for cutaneous T cell lymphoma and Emend®. Earlier in his career, Dr. Atillasoy worked with the Medical Affairs Departments at Sandoz and Novartis Pharmaceuticals, where he supported licensure of anti-infective, dermatology, tissue engineered and cell therapy products, including Apligraf®.*
In addition to his professional accomplishments, Dr. Atillasoy was selected and currently serves as the industry representative to the U.S. Food and Drug Administration (FDA) Dermatologic and Ophthalmologic Drugs Advisory Committee and served as Merck’s senior representative to the PhRMA Regulatory Steering Group and the BIO Vaccine Regulatory Advisory Committee. Dr. Atillasoy has published papers on a range of topics, including infectious disease, gene therapy, melanoma, dermatology, and tissue engineering.
Dr. Atillasoy is a graduate of the Yale University School of Medicine, where he was recognized as a Farr scholar, and continues to serve as a class officer. He completed his medical internship at Yale-New Haven Hospital and his dermatology residency at the University of Pennsylvania. He conducted research in carcinogenesis and gene therapy at the Wistar Institute. Dr. Atillasoy has received executive management and leadership training at institutions such as the Wharton School of the University of Pennsylvania and the UCLA Anderson School of Management. He maintains a voluntary Clinical Associate faculty position at the University of Pennsylvania. He graduated summa cum laude with a Bachelor of Arts degree in English from the City University of New York.
How do I contact Ercem Atillasoy?
Has Ercem Atillasoy been buying or selling shares of AlloVir?
Ercem Atillasoy has not been actively trading shares of AlloVir during the last quarter. Most recently, Ercem Atillasoy sold 4,639 shares of the business's stock in a transaction on Tuesday, January 25th. The shares were sold at an average price of $8.24, for a transaction totalling $38,225.36. Learn More on Ercem Atillasoy's trading history.
Who are AlloVir's active insiders?
Are insiders buying or selling shares of AlloVir?
In the last year, AlloVir insiders bought shares 1 times. They purchased a total of 2,930,870 shares worth more than $10,990,762.50. In the last year, insiders at the sold shares 44 times. They sold a total of 195,900 shares worth more than $287,187.73. The most recent insider tranaction occured on April, 22nd when CAO Brett R Hagen sold 480 shares worth more than $360.00. Insiders at AlloVir own 40.0% of the company.
Learn More about insider trades at AlloVir. Information on this page was last updated on 4/22/2024.
